Methodological insights and clinical outcomes in ALS and FTLD: lessons from the SPIN cohort

Data-driven neuropathology modelling of neurodegenerative disorders: how to implement AI?

This scientific commentary refers to ‘Data-driven modelling of tau pathology reveals distinct progressive supranuclear palsy subtypes’ by Cullinane et al. (https://doi.org/10.1093/brain/awag131).

Protein Biomarkers in Risk and Prognosis of Amyotrophic Lateral Sclerosis

Plasma and cerebrospinal fluid (CSF) protein biomarkers in amyotrophic lateral sclerosis (ALS) may provide insight into disease mechanisms and yield clinically useful biomarkers.

CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS–FTD Spectrum: A Systematic Narrative Review and Evidence Map

Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology...

Identifying Modifiable Factors and Their Joint Effect on Amyotrophic Lateral Sclerosis: A Prospective Cohort Study in the UK Biobank

Hypothesis‐driven studies have linked numerous risk factors to amyotrophic lateral sclerosis (ALS). However, the full extent of their diversity and co‐occurrence has not been adequately appreciated. This study aims to comprehensively explore the modifiable risk factors for ALS and to evaluate the potential benefit of c...

Rethinking multiple sclerosis therapy beyond clinical phenotypes.

Sormani et al. argue that multiple sclerosis should be viewed as a biological continuum rather than distinct clinical forms. Evidence from recent trials suggests that therapies targeting shared biological mechanisms can slow disability progression across the disease spectrum, supporting a shift away from traditional cl...

ALS phenotype is influenced by age, sex, and genetics A population-based study